Pharmacological Proteostasis-Resilience Therapies for Preserving Organ Function During Aging

Abstract

The progressive decline of organ function with aging is strongly associated with disturbances in proteostasis the cellular machinery responsible for maintaining protein homeostasis. Pharmacological strategies that enhance proteostasis resilience have emerged as promising avenues to preserve tissue function, delay age-related pathologies, and improve healthspan. This review synthesizes contemporary evidence on the mechanisms, efficacy, and clinical implications of pharmacological proteostasis-resilience therapies in the context of aging, highlighting key advancements, practical considerations, and current guideline recommendations for healthcare professionals managing aging populations.

Introduction

Aging is characterized by the gradual loss of physiological integrity, leading to impaired organ function and increased disease susceptibility. Central to this process is the disruption of proteostasis, which encompasses the balance of protein synthesis, folding, trafficking, and degradation. With age, the decline in proteostasis mechanisms contributes to protein aggregation, cellular dysfunction, and the onset of various age-related diseases such as neurodegeneration, cardiomyopathies, and metabolic syndromes. Targeting proteostasis through pharmacological interventions offers a novel paradigm for mitigating the deleterious effects of aging on organ systems.

Epidemiology / Disease Burden

The global population is experiencing unprecedented increases in life expectancy, with the proportion of individuals aged 65 and over projected to double by 2050. Age-related diseases, closely linked to proteostasis failure, account for a significant proportion of morbidity and healthcare expenditures worldwide. Disorders such as Alzheimer's disease, Parkinson's disease, and age-associated cardiac dysfunction are increasing in prevalence, underscoring the urgent need for interventions that can preserve organ function and reduce the burden of chronic illness in aging cohorts.

Pathophysiology

Proteostasis involves a complex network of molecular chaperones, proteolytic systems (including the ubiquitin-proteasome system and autophagy-lysosome pathway), and cellular stress responses such as the unfolded protein response (UPR). Aging impairs these systems, resulting in the accumulation of misfolded and damaged proteins, cellular stress, and activation of pro-inflammatory pathways. This proteostatic imbalance underlies many hallmarks of aging, including cellular senescence, mitochondrial dysfunction, and chronic inflammation, ultimately driving organ decline.

Risk Factors

Multiple intrinsic and extrinsic factors accelerate proteostasis deterioration. Genetic predispositions, chronic metabolic stress, environmental toxins, sedentary lifestyle, and comorbidities such as diabetes and obesity exacerbate proteostatic stress. Variability in the expression and function of molecular chaperones, proteases, and stress response pathways contribute to individual susceptibility to proteostasis-related organ dysfunction during aging.

Clinical Features

Clinically, impaired proteostasis manifests as progressive loss of organ function, ranging from cognitive decline in neurodegenerative diseases to reduced cardiac output in heart failure and diminished renal filtration in chronic kidney disease. Subtle early signs may include fatigue, mild cognitive impairment, sarcopenia, and decreased physiological reserve, often preceding overt organ failure. Biomarkers of proteostasis disruption, such as circulating misfolded proteins or altered chaperone levels, are under investigation for early detection and monitoring of disease progression.

Diagnosis

Diagnosis of proteostasis-related dysfunction is inherently challenging due to the multifactorial nature of aging. Current approaches include clinical assessment of organ-specific function, neurocognitive testing, and emerging molecular biomarkers that reflect protein aggregation, chaperone activity, or proteolytic system competence. Advanced imaging modalities and omics technologies are increasingly employed in research settings to elucidate proteostatic alterations in aging tissues, supporting both diagnosis and therapeutic monitoring.

Treatment & Management

Conventional management of age-related organ dysfunction focuses on symptom control and risk factor modification. However, the pharmacological enhancement of proteostasis is gaining traction as a disease-modifying strategy. Interventions targeting molecular chaperones, proteasome activators, and autophagy inducers are under active investigation. Lifestyle interventions such as caloric restriction and exercise also support proteostasis but may be insufficient in advanced age or disease states, highlighting the need for pharmacological augmentation.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in the development of proteostasis-resilience therapies. Pharmacological chaperones, such as tafamidis and migalastat, are clinically approved for specific protein-misfolding disorders and are being repurposed for broader aging indications. Proteasome enhancers, autophagy modulators (e.g., rapamycin, spermidine), and small molecules activating the heat shock response (e.g., HSP90 inhibitors) show promise in preclinical and early clinical studies. Novel agents targeting the unfolded protein response, such as ISRIB, are under evaluation for neurodegenerative and systemic aging phenotypes. Combination therapies and precision approaches based on individual proteostatic profiles represent the future direction of the field.

Guideline Recommendations

While formal clinical guidelines for the routine use of proteostasis-resilience agents in general aging populations are still evolving, expert consensus supports their use in selected cases of protein-misfolding disease and in clinical trials. Current recommendations emphasize the importance of early identification of proteostasis impairment, risk stratification, and integration of lifestyle and pharmacological interventions tailored to patient-specific needs. Ongoing trials and real-world evidence will inform future updates to clinical guidelines and best practice recommendations.

Conclusion

Pharmacological proteostasis-resilience therapies represent a transformative approach to preserving organ function during aging. The integration of mechanistic insights, clinical evidence, and emerging therapeutics holds promise for reducing the burden of age-related diseases and extending healthspan. Continued research, multidisciplinary collaboration, and evidence-based implementation will be essential to realize the full potential of proteostasis-targeted interventions in clinical practice.